Lacosamide Overview Categories 5 Anticonvulsants and Antiepileptics Page headings Overview Primary Characterstics Indications Pharmacokinetics Contraindications Drug Interactions Side Effects Dosage High Risk Groups Warning / Precautions Storage Conditions Interference in Pathology Brands of Lacosamide Manufacturers of Lacosamide Primary Characterstics Indications Back to top Pharmacokinetics Back to top Contraindications Back to top Drug Interactions Back to top Side Effects Back to top Dosage Lacosamide's dosage details are as follows: Dose Single Dose Frequency Route Instructions Adult Dosage 50 to 200 mg120 (125)12 hourlyPO and IVWhen switching from oral VIMPAT, the initial total daily intravenous dosage of VIMPAT should be equivalent to the total daily dosage and frequency of oral VIMPAT. At the end of the intravenous treatment period, the patient may be switched to VIMPAT oral administration at the equivalent daily dosage and frequency of the intravenous administration. Paedriatic Dosage (20kg) Neonatal Dosage (3kg) No data regarding the neonatal dosage details of Lacosamide is available. High Risk Groups Back to top Warning / Precautions Back to top Storage Conditions Back to top Interference in Pathology Back to top Brands / Trade Names of Lacosamide Back to top Manufacturers of Lacosamide in Pakistan Genix Hilton MAQ Mass Back to top Previous Drug Generic - Next Drug Generic
Lacosamide Overview Categories 5 Anticonvulsants and Antiepileptics Page headings Overview Primary Characterstics Indications Pharmacokinetics Contraindications Drug Interactions Side Effects Dosage High Risk Groups Warning / Precautions Storage Conditions Interference in Pathology Brands of Lacosamide Manufacturers of Lacosamide Primary Characterstics Indications Back to top Pharmacokinetics Back to top Contraindications Back to top Drug Interactions Back to top Side Effects Back to top Dosage Lacosamide's dosage details are as follows: Dose Single Dose Frequency Route Instructions Adult Dosage 50 to 200 mg120 (125)12 hourlyPO and IVWhen switching from oral VIMPAT, the initial total daily intravenous dosage of VIMPAT should be equivalent to the total daily dosage and frequency of oral VIMPAT. At the end of the intravenous treatment period, the patient may be switched to VIMPAT oral administration at the equivalent daily dosage and frequency of the intravenous administration. Paedriatic Dosage (20kg) Neonatal Dosage (3kg) No data regarding the neonatal dosage details of Lacosamide is available. High Risk Groups Back to top Warning / Precautions Back to top Storage Conditions Back to top Interference in Pathology Back to top Brands / Trade Names of Lacosamide Back to top Manufacturers of Lacosamide in Pakistan Genix Hilton MAQ Mass Back to top Previous Drug Generic - Next Drug Generic